Yes Doctors, You Were Right. The Data Were Wrong: One Organization's Data Quality Journey.

In 2012, publicly released reports indicated that the health outcomes at St. Joseph's Health Centre, Toronto (SJHC), may not be of the same quality when compared with those at peer hospitals. This surprised the leaders within the organization given that SJHC had a sound reputation for quality and patient safety within the sector.

[Descriptive study of healthcare professionals' management of tick bites].

Introduction: Rural primary health centers frequently treat patients with tick bites. This study compares everyday clinical practice at our primary healthcare center to practices recommended by current scientific evidence.

Purpose: To describe the everyday management of tick bites by different healthcare professionals and to compare this management to evidence-based therapy guidelines.

Estrogen receptor alpha and beta expression in a case matched series of serous and endometrioid adenocarcinomas of the ovary.

Objective: The purpose of this study was to analyze estrogen receptor alpha and beta (ERalpha, ERbeta) expression in a stage and grade matched cohort of patients with serous and endometrioid adenocarcinoma of the ovary.

Methods: Forty-two patients from 1991 to the present were found to have the diagnosis of endometrioid adenocarcinoma of the ovary and have tissue available for analysis. Of these 42, ten were selected for analysis.

Phase I trial of gemcitabine, administered as a standard and constant dose-rate infusion, in combination with paclitaxel in patients with advanced solid tumors (LOA-2).

The major purposes of this study were to determine the maximally tolerated dose (MTD), dose-limiting toxicity (DLT), toxicity profile, and antitumor activity of gemcitabine and paclitaxel combination therapy when administered to patients with advanced solid tumors, using two infusion schedules of each agent. Paclitaxel was administered on day 1, followed by gemcitabine, and gemcitabine alone was administered on day 8, of each 21-day treatment course. In the initial phase of the trial, paclitaxel was administered during 3 hours and gemcitabine during 30 minutes (schedule A).